20896-44-0

Basic information

• Product Name: 2,5-diaminobenzene sulfonamide
• Synonyms: 2,5-diaminobenzene sulfonamide
• CAS NO: 20896-44-0
• Molecular Formula: C₆H₉N₃O₂S
• Molecular Weight: 187.2196
• Product Categories: Nitro / Nitriles
• Mol File: 20896-44-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 483.14 °C at 760 mmHg
• Flash Point: 245.994 °C
• Appearance: /
• Density: 1.523 g/cm³
• Storage Temp.: 2-8°C
• PKA: 10.55±0.60(Predicted)
• CAS DataBase Reference: 2,5-diaminobenzene sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-diaminobenzene sulfonamide(20896-44-0)
• EPA Substance Registry System: 2,5-diaminobenzene sulfonamide(20896-44-0)

Safety Data

• Hazardous Substances Data: 20896-44-0(Hazardous Substances Data)

Usage

General Description

2,5-diaminobenzene sulfonamide, also known as sulfanilamide, is a synthetic organic compound that belongs to the class of sulfonamide antibiotics. It is used in the treatment of various bacterial infections, particularly in the urinary tract. The compound works by inhibiting the growth of bacteria, thus helping the body's immune system to fight off the infection. Sulfanilamide is also used in the production of dyes, drugs, and pesticides, making it a versatile and widely used chemical compound. However,

Upstream product

• 54734-85-9 2-amino-5-nitrobenzenesulfonamide 
• 1000312-84-4 N-(1,1,3-trioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,2,4]thiadiazin-7-yl)methanesulfonamide 
• 1000313-17-6 2-benzylamino-5-nitro-benzenesulfonamide 
• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 5455-59-4 2-Nitrobenzenesulfonamide 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 96-75-3 2-amino-5-nitro-benzenesulfonic acid 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 100-00-5 4-chlorobenzonitrile 
• 5825-62-7 N-(4-nitrophenyl)methanesulfonamide 
• 30693-53-9 2-amino-5-nitrobenzenesulfonic acid sodium salt 

Downstream Products

• 1370714-06-9 N-[3-(1-benzyl-1H-indol-3-yl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methansulfonamide 
• 1000313-18-7 N-(4-(methanesulfonylamino)-2-sulfamoyl-phenyl)malonamic acid ethyl ester 
• 1000313-19-8 N-(4-methanesulfonylamino-2-sulfamoylphenyl)malonamic acid methyl ester 
• 1071517-39-9 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 
• 1071520-44-9 (1S,2R,3S,4R)-3-{(4-fluorobenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)acetyl]amino}bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071519-59-9 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-arginine salt 
• 1071519-62-4 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-lysine salt 
• 1071519-66-8 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide sodium salt 
• 1071519-68-0 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide potassium salt 
• 1071517-44-6 N-{3-[(1S,2R,7S,8R)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1071518-93-8 N-{3-[(2S,7R)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1071517-31-1 N-{3-[(1S,2S,7R,8R)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1071517-35-5 N-{3-[(1R,2R,7S,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1071517-60-6 N-{3-[(1S,2R,7S,8R)-3-(4-fluoro-3-methylbenzyl)-6-hydroxy-4-oxo-11-oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 

Relevant articles and documents

Des-A-ring benzothiadiazines: Inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase

In our program to discover non-nucleoside, small molecule inhibitors of genotype 1 HCV polymerase, we investigated a series of promising analogs based on a benzothiadiazine screening hit that contains an ABCD ring system. After demonstrating that a methyl

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives

This work presents the first structure-based activity prediction model for benzothiadiazines against various genotypes of HCV NS5b polymerase (1a, 1b and 4).The model is a comprehensive workflow of structure-based field template followed by guided docking. The field template was used as a pre-filter and a tool to provide hits in good orientation and position. It was created based on detailed molecular interaction field analysis which includes Topomer CoMFA, grid independent analysis and Superstar. On the other hand, Guided docking was used as a refinement and assessment tool. It was actively directed by two scores: Moldock score as an interaction descriptor (r2 = 0.65) and a template similarity score as a measure for accurate binding-mode compliance. The docking template was based on energy-based pharmacophore analysis. The whole procedure was formulated and tweaked for both screening (ROC of AUC = 0.91) and activity prediction (r2 of 0.8) for the genotype 1a. In order to widen the model scope, linear interaction energy was used as a tool for predicting activities of other genotypes based on the docked ligand poses while mutation binding energy was used to investigate the effect of each amino acid mutation in genotype 4. The model was applied for structure-based fragment hopping by screening a library designed by reaction enumeration. A top scoring hit was used to generate a focused library such that it has lower TPSA than the original class ligands and thus better pharmacokinetic properties. After that, experimental validation was carried out by the synthesis of this library and its biological evaluation which yielded compounds that exhibit EC50 ranging from 1.86 to 23 μM.

4-Hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.